| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration
First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory clearance
Preparations for dose-ranging Phase 2 study of NPM-139 to occur in parallel with Phase 1 study
ALAMEDA, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing novel, ultra long-acting drug implants, today announced plans to initiate a Phase 1 clinical study in the NPM-139 semaglutide implant program in the first half of 2026, pending regulatory clearance. The Company is also preparing to initiate a Phase 2 clinical study of NPM-139 pending enabling results from the Phase 1 study and regulatory feedback. The NPM-139 clinical program will evaluate the Company's investigational semaglutide implant for chronic weight management in patients who are either obese or overweight with a related comorbidity.
Posted In: VANI
